Invenomic Capital Management’s Stride LRN Stock Holding History

Invenomic Capital Management’s Portfolio LRN Stock Details LRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-92,100	Closed	-$2.96M	–	137
2021 Q2	$2.96M	Buy	+92,100	New	+$2.75M	0.71%	32

Other funds holding LRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Invenomic Capital Management's LRN Position: Q2 2024 in Review

Invenomic Capital Management sold out of Stride (LRN) in Q2 2024, closing a stake of 67,739 shares — an estimated $4.27M sold.

Invenomic Capital Management first reported a position in LRN in Q1 2020 and held it in 17 quarters. The position peaked at $16M in Q3 2023. 329 funds tracked by Wall St. Rank hold LRN as of Q2 2024.

Invenomic Capital Management reported no remaining Stride position as of Q2 2024 after selling out during the quarter.
Invenomic Capital Management sold 67,739 Stride shares in Q2 2024, an estimated $4.27M.
Invenomic Capital Management first reported a position in Stride in Q1 2020 and held it in 17 quarters.
Invenomic Capital Management's Stride position peaked at $16M in Q3 2023.
329 funds tracked by Wall St. Rank held Stride as of Q2 2024.

Based on Invenomic Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.